Literature DB >> 24503978

Implementation fidelity of self-administered transcutaneous electrical nerve stimulation (TENS) in patients with chronic back pain: an observational study.

Edward J Pallett1, Patricia Rentowl, Mark I Johnson, Paul J Watson.   

Abstract

OBJECTIVES: The efficacy of transcutaneous electrical nerve stimulation (TENS) for pain relief has not been reliably established. Inconclusive findings could be due to inadequate TENS delivery and inappropriate outcome assessment. Electronic monitoring devices were used to determine patient compliance with a TENS intervention and outcome assessment protocol, to record pain scores before, during, and after TENS, and measure electrical output settings.
METHODS: Patients with chronic back pain consented to use TENS daily for 2 weeks and to report pain scores before, during, and after 1-hour treatments. A ≥ 30% reduction in pain scores was used to classify participants as TENS responders. Electronic monitoring devices "TLOG" and "TSCORE" recorded time and duration of TENS use, electrical settings, and pain scores.
RESULTS: Forty-two patients consented to participate. One of 35 (3%) patients adhered completely to the TENS use and pain score reporting protocol. Fourteen of 33 (42%) were TENS responders according to electronic pain score data. Analgesia onset occurred within 30 to 60 minutes for 13/14 (93%) responders. It was not possible to correlate TENS amplitude, frequency, or pulse width measurements with therapeutic response. DISCUSSION: Findings from TENS research studies depend on the timing of outcome assessment; pain should be recorded during stimulation. TENS device sophistication might be an issue and parameter restriction should be considered. Careful protocol design is required to improve adherence and monitoring is necessary to evaluate the validity of findings. This observational study provides objective evidence to support concerns about poor implementation fidelity in TENS research.

Entities:  

Mesh:

Year:  2014        PMID: 24503978     DOI: 10.1097/AJP.0b013e31828dc828

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  8 in total

1.  Covid-19 Outbreak Highlights: Importance of Home-Based Rehabilitation in Orthopedic Surgery.

Authors:  Amin Azhari; Ali Parsa
Journal:  Arch Bone Jt Surg       Date:  2020-04

Review 2.  Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults.

Authors:  Mark I Johnson; Leica S Claydon; G Peter Herbison; Gareth Jones; Carole A Paley
Journal:  Cochrane Database Syst Rev       Date:  2017-10-09

Review 3.  Medical devices for restless legs syndrome - clinical utility of the Relaxis pad.

Authors:  Ulrike H Mitchell
Journal:  Ther Clin Risk Manag       Date:  2015-12-03       Impact factor: 2.423

4.  Fixed-site high-frequency transcutaneous electrical nerve stimulation for treatment of chronic low back and lower extremity pain.

Authors:  Shai N Gozani
Journal:  J Pain Res       Date:  2016-06-28       Impact factor: 3.133

5.  Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation in chronic pain: a large-scale, observational study.

Authors:  Xuan Kong; Shai N Gozani
Journal:  J Pain Res       Date:  2018-04-09       Impact factor: 3.133

6.  Impact of transcutaneous electrical nerve stimulation on sleep in chronic low back pain: a real-world retrospective cohort study.

Authors:  Shai N Gozani; Thomas C Ferree; Martin Moynihan; Xuan Kong
Journal:  J Pain Res       Date:  2019-02-25       Impact factor: 3.133

Review 7.  Remote Analgesic Effects Of Conventional Transcutaneous Electrical Nerve Stimulation: A Scientific And Clinical Review With A Focus On Chronic Pain.

Authors:  Shai N Gozani
Journal:  J Pain Res       Date:  2019-11-26       Impact factor: 3.133

Review 8.  Resolving Long-Standing Uncertainty about the Clinical Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) to Relieve Pain: A Comprehensive Review of Factors Influencing Outcome.

Authors:  Mark I Johnson
Journal:  Medicina (Kaunas)       Date:  2021-04-14       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.